Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. - Wikidata - awgldk - TriplyDB

Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy.

Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy.

http://www.wikidata.org/entity/Q34506935

about

Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets CCR6+ B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis A review of the application of inflammatory biomarkers in epidemiologic cancer research.Prognostic significance of interleukin 17 in cancer: a meta-analysis.Prognostic significance of interleukin-17 in solid tumors: a meta-analysis.Expression of Th17 cell population regulatory cytokines in laryngeal carcinoma - Preliminary study HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma.Postoperative Low Absolute Lymphocyte Counts may Predict Poor Outcomes of Hepatocellular Carcinoma After Liver Resection Interleukin-8 and interleukin-17 for cancer.Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful?Pathogenic Role of IL-17-Producing Immune Cells in Obesity, and Related Inflammatory Diseases.Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma.Interleukin-17A and interleukin-17F gene polymorphisms and hepatitis B virus-related hepatocellular carcinoma risk in a Chinese population.The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review.Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments.Local and systemic Th17 immune response associated with advanced stage colon cancer.Clinical relevance of the number of interleukin-17-producing CD 8+ T cells in patients with gastric cancer.Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma.IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.

P2860

Q28071678-1165B2C5-0D3E-4EF0-8146-5E8D71DC922D Q33733021-52CF33E2-E5F8-49DB-82BD-09480ADFEEC9 Q34135803-F2738646-9CB8-4691-A498-CB9A2952B8E3 Q34547722-A985DC52-F17E-41C1-9159-FDE883ECECCA Q36046142-DCB3816B-DE8B-4002-B27A-23263FF41375 Q36243933-B46D6C1E-268C-4EBD-8E16-355A97D92DB5 Q36364376-0CBC0368-E3AD-4CA5-9311-8296271A0677 Q36720072-5ADB0002-8D6B-46A6-A444-5FB4DEFF65F9 Q38199524-55C7C25D-57F7-4EB3-974E-C7F08BCF343F Q38349665-CA43B95E-363C-4E90-9F9E-7F4C7002EB2B Q38466831-71E3D7A8-0E82-4FEF-8D54-E21E9D16E08D Q39434888-1B5E7A36-F126-4BFF-94B3-98DADB1141D2 Q40707004-89697AC0-3B63-44B7-B50C-8F9FB882AE91 Q42180513-97E39FF0-DEE4-4FBC-A131-9FA8B1309323 Q42600273-111A6D36-D844-413E-849A-9D8A9D465C4C Q45400426-E391EF21-6034-474A-88A3-5BC2C9D8822C Q51250611-582EC502-842B-4C22-B67D-7B68010ABD24 Q52951871-CEDE9CBB-363A-45AB-97C3-51D3E8F0DB6B Q53245555-5D2DAF4B-3348-4AC0-AC49-464875E4E93C Q54940618-4DEC9729-E8FF-4A58-AAA4-E79D6771A5FD

P2860

Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy.

http://www.wikidata.org/entity/Q34506935

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@ast

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@en

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@nl

type

label

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@ast

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@en

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@nl

prefLabel

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@ast

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@en

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@nl

P1433

Q34506935-34369F01-B7E8-4DCB-B441-CF448397C381

P1476

Q34506935-F8D9F4C5-5054-4CB3-BDA5-B2EF53FADFF5

P2093

Q34506935-039AE1BC-94B5-43D7-8FDA-7C0222170E3D

Q34506935-2C6483AE-6EB6-4E95-B009-4916CAB1EA38

Q34506935-340C5B55-31EA-463E-9817-4682D5F73060

Q34506935-4E74A5C6-02CF-4CA1-9009-8EA8FE3A2129

Q34506935-6341388F-FDFA-47D8-8092-8D2EB105E408

Q34506935-8A8F03E2-CA18-4908-94E7-067B7450A44A

Q34506935-8DE52B1B-08EE-4484-856B-1F465B188383

Q34506935-8FAED887-FC9F-4CF2-BDA8-46DCBDDB5D3A

Q34506935-A4FBD56B-5C26-4CB1-A67C-4C37C26E4ADA

Q34506935-AD4DDFBD-6463-40AA-A8A5-E8AD090E267A

P2860

Q34506935-0152FC07-A1E2-4760-B9D7-29BCA5984F03

Q34506935-01612706-A51D-4ECE-89DE-E7CE7D9D2F7A

Q34506935-01F6ED9C-91D1-425B-AB0A-95028FDB1E8C

Q34506935-04CAA52D-60FF-4885-BD41-6B28CE1C2899

Q34506935-14B70B60-02ED-4C18-AE27-FB98FF4F6754

Q34506935-1B2914BA-0569-4D67-9E62-8C7F57EB6917

Q34506935-36550AA8-A170-47BE-B78B-4029E9F10216

Q34506935-3D9864B3-9AF9-41D7-B215-61200B1FAC27

Q34506935-4B787F80-09D3-4F1A-BC0B-85CE4DDE6799

Q34506935-50B28F9C-6167-4945-8DE0-30EB1EE9E6AB

P304

Q34506935-4D283102-7356-4F95-A8BB-030664B5BE3F

P31

Q34506935-B32E7CC6-4571-4231-8BE6-1493B74A7BD4

P356

Q34506935-C9F785E6-C15E-4FFC-8284-637452938331

P407

Q34506935-A6DF72E3-981F-4FB6-82EC-E5AA9D55E5DF

P433

Q34506935-C05D0C92-3245-4E94-A18E-BFA34AE2918E

P478

Q34506935-51B530A9-5999-454D-9E01-5AE9FCBC963B

P577

Q34506935-AAA1D27C-C5B3-40C9-9F67-DCFC23AEB2FC

P5875

Q34506935-D976C81F-2877-4ADD-985D-1378F08FB502

P698

Q34506935-1E5F1951-C8E7-4783-A337-7C99D5858108

P921

Q34506935-DAFFAD42-7140-415E-91F8-44584BB5B046

P932

Q34506935-72504891-22ED-4F9A-BD45-8F2667E1C4F9

P356

JOURNAL.PONE.0050035

P1433

P1476

Elevated pretherapy serum IL17 ...... ce after curative hepatectomy.

@en

P2093

Chunfeng Qu

http://www.w3.org/2001/XMLSchema#string

Jianxiong Wu

http://www.w3.org/2001/XMLSchema#string

Jun Du

http://www.w3.org/2001/XMLSchema#string

Liguo Liu

http://www.w3.org/2001/XMLSchema#string

Liming Wang

http://www.w3.org/2001/XMLSchema#string

Mengya Zang

http://www.w3.org/2001/XMLSchema#string

Qian Li

http://www.w3.org/2001/XMLSchema#string

Weiqi Rong

http://www.w3.org/2001/XMLSchema#string

Yawei Zhang

http://www.w3.org/2001/XMLSchema#string

Ying Wang

http://www.w3.org/2001/XMLSchema#string

P2860

LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma

IL-17 mediated inflammation promotes tumor growth and progression in the skin

Differentiation of effector CD4 T cell populations (*)

Development, cytokine profile and function of human interleukin 17-producing helper T cells

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

A specific splicing variant of SVH, a novel human armadillo repeat protein, is up-regulated in hepatocellular carcinomas.

Pathogenesis of hepatitis B virus infection

Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression.

Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.

IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells

P304

e50035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0050035

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233889785

http://www.w3.org/2001/XMLSchema#string

P698

23227158

http://www.w3.org/2001/XMLSchema#string

P921

P932

3515597

http://www.w3.org/2001/XMLSchema#string